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Desmoid tumours (DT), also known as fibromatosis (aggressive, deep or desmoid-type), are a rare 
and unusual soft tissue neoplasm. Desmoid tumours result from monoclonal proliferation of 
myofibroblastic tissue which tends to infiltrate and recur locally, but never metastasise.1,2 Despite 
their classification as a benign neoplasm, their capacity for local invasion may cause significant 
morbidity and even death. Therefore, appropriate and timeous treatment is essential. McFarlane 
first described the condition in 18323 and the term ‘desmoids’ (from the Greek ‘desmos’, meaning 
band- or tendon-like) was coined by Müller in 1838.4 Desmoid tumours account for 0.03% of all 
neoplasms and 3% of soft tissue tumours5,6 and have an estimated incidence of 2.4–4.3 per million 
people per year in the general adult population.1 They commonly originate from deep musculo-
aponeurotic structures, but also develop intra-abdominally.2
Desmoid tumours can occur sporadically (around 85%7) or in association with familial 
adenomatous polyposis (FAP),1 the latter combination being termed Gardener’s syndrome.8 
Pregnancy is an associated condition (either during or following a pregnancy), suggesting high 
oestrogen states as contributory.5 The association with antecedent trauma or previous surgery9 
may implicate a dysregulated wound healing process in the pathogenesis of this condition.8
Treatment of DT is complicated by the heterogeneity of the condition with regard to natural history, 
location and symptomatology. Surgery aims to completely excise the tumour with limited 
functional or cosmetic morbidity, and is generally indicated for symptomatic or progressive DT.10 
Background: Desmoid tumours (DT) are rare soft tissue tumours that do not metastasise but 
are locally aggressive. Management options are varied and the response to treatment can be 
unpredictable. 
Aim: The aim of this study was to describe the clinical presentation, management strategies 
and outcomes for adult patients who were treated for DT.
Setting: The study was conducted at Groote Schuur Hospital in Cape Town, South Africa, and 
all patients from 2003 to 2016 who presented with DT were included.
Method: This was a retrospective review of records. Data collected included: demographics, 
DT-associated conditions, site and size of tumour, histological findings, treatment modalities, 
follow-up and outcomes. 
Results: Seventy patients with histologically confirmed DT were identified. The majority were 
women (86%) and 77% presented with a painless mass. The commonest site was the anterior 
abdominal wall (47%). Definitive surgery was performed in 46 (66%) patients, whereas 
13 (19%) had definitive radiotherapy. Nine patients received adjuvant radiotherapy post-
surgery for involved or close margins. Recurrence developed in 20% of patients post-surgery. 
In the primary radiotherapy group, one patient had disease progression. Two patients with 
mesenteric DT died because of bowel obstruction.
Conclusion: This retrospective review of patients affected by DT at a single centre demonstrates 
the rarity of the condition, the unpredictable natural history and the variety of treatment 
options available. Many of our findings are similar to other published studies, except the mean 
size of DT which was bigger. Treatment outcomes following surgery or radiotherapy seem 
acceptable, although study limitations are noted. 
Keywords: desmoid tumour; desmoid fibromatosis; review; management; recurrence; 
outcome.
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However, recurrence post-surgery is common and is higher in 
patients with macroscopically positive margins.7 Radiotherapy 
(RT) can be used as a definitive treatment modality with 
results that compare favourably to surgery.11 Also, when used 
in combination with surgery, RT appears to decrease local 
recurrence rates in patients with incomplete surgical excision, 
particularly following surgery for recurrent tumours.7 
Systemic therapies, including cytotoxic therapies, hormonal 
therapies, anti-inflammatory agents and biologicals, are also 
occasionally used.12 Recently, practice guidelines in many 
countries have shifted to more expectant management of DT 
because of increasing evidence that a significant percentage of 
these tumours may regress or remain stable without any 
intervention.10,13,14
There are limited published data on this condition in low- 
and middle-income countries. As part of a review of local 
treatment protocols, the study was conducted to assess the 
demographics, clinical characteristics, treatment modalities 
and outcomes of adult patients who were diagnosed with 
DT, over a 13-year period. This study aims to describe the 
demographic and clinical characteristics, management 
strategies, local recurrence and outcomes for all patients 
treated with DT over this period.
Methods
This was a retrospective review of all patients with 
histologically confirmed DT who were managed at a single 
tertiary referral hospital from the 01 January 2003 to 31 
December 2016. Patients younger than 18 years of age were 
excluded and there were no patients identified who had 
recurrence at initial presentation.
Eligible patient records were identified using established 
databases from the departments of General Surgery (Surgical 
Oncology Unit) and Radiation-Oncology. National Health 
Laboratory Services (NHLS) pathology records were also 
obtained for all patients diagnosed with this condition during 
the study period. Data collected included: patient 
demographics, site and size of DT (combination of clinical, 
imaging and operative specimen measurement), presenting 
symptoms, biopsy technique used, associated conditions or 
risk factors, β-catenin status on immunohistochemistry, 
primary and other treatment modalities, recurrence rates 
following surgery, post-operative complications according to 
Clavien–Dindo classification,15 mortality events and total 
duration of follow-up for each patient from the time of 
diagnosis. Response to definitive RT was assessed according 
to the response evaluation criteria in solid tumours (RECIST) 
criteria.16 Data were stored in a password-protected Microsoft 
Excel© Spreadsheet.
Statistical considerations
Univariate analyses were conducted given the descriptive 
nature of the study. Numerical variables were described 
using measures of central tendency and dispersion, 
depending on the distribution of the data. Categorical 
variables were analysed using proportions and two-way 
frequency tables.
Ethical considerations
Ethical clearance for the study was granted by the Human 
Research Ethics Committee of the Faculty of Health Sciences 
at the University of Cape Town (HREC REF: 679/2017).
Results
Patient and tumour characteristics
A total of 70 records of patients who had DT were identified 
for analysis, as presented in Table 1. The majority of patients 
(86%) were female. The median age at diagnosis was 36.5 
years. The majority of DT, 65/70 (93%), were extra-abdominal, 
and of these, mainly in the anterior abdominal wall (51%), 
trunk (29%) and limbs (15%).
The most common presenting symptom was a painless mass, 
54/70 (77%). Nine (13%) patients presented with painful 
mass, three (4%) with bowel obstruction, two (3%) reported 
TABLE 1: Demography and clinicopathological findings in patients who had 
desmoid tumours.
Variables Value % Range
Age
Median age - - 36.5 years
Interquartile range (IQR) - - 27.3–45.0 years
Sex -
Female 60/70 86 -
Male 10/70 14 -
Site -
Extra-abdominal 65/70 93 -
Abdominal wall 33/65 51 -
Trunk 19/65 29 -
Limbs 10/65 15 -
Head and neck 3/65 5 -






Familial adenomatous polyposis (FAP) 
Previous regional surgery
Trauma
Pregnancy-related desmoid tumours 
Pregnant – 6-months post-partum 7/17 41 -
> 6-months – 2-years post-partum 10/17 49 -
Presenting symptoms
Painless mass 54/70 77 -
Painful mass 9/70 13 -
Bowel obstruction 3/70 4 -
Local pain only 2/70 3 -
Unknown 2/70 3 -
Tumour size (N = 58)† 9 cm - 2 cm – 29 cm
Diagnosis
Core biopsy 45/70 64 -
Incisional biopsy 13/70 19
Excisional biopsy 10/70 14 -
Unknown 2/70 3 -
β-catenin staining
Positive 36/38 95 -
Negative 2/38 5 -
†, Combination of clinical, imaging and operative specimen measurement.
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pain localised to the mass and the symptom was not recorded 
in two (3%) patients. Six (9%) of the cohort were known to 
have FAP. Of the other factors known to be associated with 
DT, 7/70 (24%) were pregnancy-related, 12/70 (17%) had 
previous regional surgery and 4/70 (6%) had a history of 
previous trauma to the area. Of the 17 patients with 
pregnancy-related DT, 7/17 (41%) were pregnant or up to 
6-months post-partum (one of these patients was noted to 
have had regional surgery prior to this pregnancy) and the 
remaining 10/17 (51%) were diagnosed between 6 and 24 
months after delivery. Thirty-one patients (44%) had no 
known associated condition.
The diagnosis was based on histological samples obtained 
by core-needle biopsy in the majority of cases 45/70 (64%), 
whereas excisional biopsy was relied on in 13/70 (19%) and 
incisional biopsy in 10/70 (14%). The original diagnostic 
investigation was not specified in 2/70 (3%) of the records. 
Immunohistochemistry staining for β-catenin was performed 
in 38/70 (54%) cases and 36/38 (95%) of these were positive. 
Of the 6 patients with confirmed FAP, only one was tested 
for β-catenin and was poistive. Tumour size was known in 
58/70 (83%) patients and ranged from 2.0 cm to 29.0 cm at 
greatest dimension, with an average size of 9.0 cm. 
Treatments and outcomes
The majority of patients, 58/70 (83%), were managed by the 
Endocrine and Oncology Surgery Unit within the Division of 
General Surgery and by the Radiation Oncology Department, 
the remainder having been managed by the Gynaecological and 
Orthopaedic services. Thirty-six (51%) patients were formally 
reviewed within a multidisciplinary team (MDT) context, which 
varied in terms of relation to primary treatment intervention, 
with many having had primary surgery prior to MDT. The 
definitive treatment modalities are depicted in Figure 1.
Surgery
Surgery was the primary treatment in 46/70 (66%) patients; 
44/70 of these were surgery performed with curative 
intent and 2/70 were palliative debulking procedures. Of 
the 44 patients who underwent surgery with curative 
intent, 28/44 (64%) had clear (R0) margins, 11/44 (25%) 
had microscopic (R1) involved margins and 2/44 (4%) 
had macroscopic (R2) involved margins; in the remaining 
3 (7%), the final histology report was not available. Twenty-six 
patients had wide local excisions of abdominal wall DT 
and of these 23 required mesh reconstruction of the 
abdominal wall defect. The surgical complications are 
shown in Table 2.
Surgery and radiotherapy
Combination treatment with surgery and RT was used in 
11 cases. Nine received adjuvant RT and 2/11 neo-adjuvant 
RT. In the adjuvant category, 8/9 cases had involved margins 
(7 = R1, 1 = R2) and one case had a close margin (2 mm). In 
the neo-adjuvant category (to downsize the tumour prior to 
surgery), one had macroscopically involved (R2) margins at 
surgery and progressed (this patient had the debulking 
surgery for tumour necrosis), and the other had clear (R0) 
margins at surgery.
Radiotherapy as definitive treatment
Definitive RT was employed in 13 patients in whom the DTs 
were deemed irresectable. Of the patients who received RT as 
definitive treatment, nine (69%) had a partial response, one 
(8%) had a complete response, two (15%) had stable disease 
and one (8%) had progressive disease as assessed using the 
RECIST criteria.11 See Figure 2.
These patients were all followed up for more than 1-year 
post-RT, with an average follow-up of 57 months (range: 13–
133 months). Radiation complications included six cases of 
skin fibrosis. The median RT dose delivered (including 
definitive, adjuvant and neo-adjuvant) was 55.0 Gy (range: 




4 1. Definitive surgery (46/70) (66%)
2. Definitive radiotherapy (13/70) (18%)
3. Systemic therapy (2/70) (3%)
4. None or unknown (9/70) (13%)









FIGURE 2: Response to definitive radiotherapy treatment. 
TABLE 2: Surgical complications (early or late) Clavien–Dindo classification system.15
Grade Complications Management No. of patients










Grade 2 Surgical site 
infections 
Oral antibiotics (in addition 
to standard wound care)
2
Grade 3a Seroma Percutaneous drain 
placement
1




Grade 4a - - -
Grade 4b - - -
Grade 5 Bowel obstruction - 2
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Systemic treatments
Of the six patients who received systemic therapy, four 
had this in combination with RT. Only two patients had 
systemic therapy as their only treatment modality with 
one receiving imatinib with a good response and one 
received tamoxifen and non-steroidal anti-inflammatory 
drugs (NSAIDs) with no demonstrable response. Two 
patients received chemotherapy (six cycles of doxorubicin), 
and two tamoxifen, as an adjunct to definitive RT. Active 
observation alone was not formally used as a primary 
management strategy in any of our patients.
Follow-up
Forty-two patients had adequate follow-up of more than 
1 year and 15 had follow-up for less than 1 year. The median 
follow-up for this combined group of patients was 29 months, 
with one patient having been followed up for 295 months 
(almost 25 years). For the remaining 13 patients, follow-up 
length could not be determined because of missing clinical 
notes.
Recurrence post-surgery
Local recurrence after surgery (surgery alone or surgery with 
RT) was only analysed in those patients who followed up for 
a year or more. This consisted of clinical examinations and 
radiological imaging. The outcomes are summarised in 
Figure 3. The total number of patients in this category was 
25/44 (57%) who had surgery, with 19/44 (43%) patients 
considered as ‘unknown’ in terms of recurrence because of 
inadequate follow-up. None of the patients with inadequate 
follow-up was noted to have evidence of recurrence at last 
follow-up. Of the 25 patients with adequate follow-up, 5/25 
(20%) had proven recurrence, and 20/25 (80%) had no 
evidence of recurrence. All patients with recurrence had 
either microscopically (three patients) or macroscopically 
(two patients) involved margins. Of the patients with no 
recurrence, 15/20 (75%) had clear (R0) resection margins and 
5/20 (25%) had microscopically involved (R1) resection 
margins, as depicted in Figure 4. The average age at 
presentation of patients who had recurrence post-surgery 








































Clear margins Microscopic margins Macroscopic margins
FIGURE 4: Surgical margins and recurrence. 
Mortality
Four patients in our cohort are known to have died, two of 
unrelated medical causes, while the other two were as a 
result of the DT. Both of the patients who had died of DT had 
intra-abdominal disease with bowel obstruction because of 
disease progression.
Discussion
The demographic profile of study patients with DT is similar 
to other published studies with the majority being female 
with a median age in the fourth decade and the majority 
being sporadic DT.17,18,19,20 Sporadic DT affects β-catenin 
production with the mutation being in the CTNNB1 gene, 
whereas in FAP-related DT, the mutation is in the 
adenomatous polyposis coli (APC) gene.12 Positive β-catenin 
immunohistochemistry in those tested (38/70 – 54%) in this 
study was much higher (95%) than the reported rate (67% 
– 80%) in other studies.21 Unfortunately those with FAP
were not all tested for β-catenin status, but the one tested
was did express β-catenin as one would expect. The average
size of desmoids in the current study was 9.0 cm (range: 2.0 
cm – 29.0 cm), which is larger than other similar reports, 
where the mean was between 6.3 cm and 7.7 cm.2,20 Larger 
size at presentation is significant as size greater than 7 cm 
has been shown to be a poor prognostic factor for 
progression-free survival.13
In terms of the location, the majority (93%) of patients 
had extra-abdominal DT which is similar to a report from a 
study involving 426 patients by Salas et al.,13 which showed 
87% of DT to be extra-abdominal. Interestingly, only one of 
the six confirmed FAP-associated DT cases was intra-
abdominal (four were located in the abdominal wall and 
one in the neck region). This preceding finding is unusual 
as the majority of reported DT associated with FAP 
are intra-abdominal, followed by the anterior 
abdominal wall. Pregnancy (previous or current) was 
noted in close to 25% patients. Similar to what is reported 
in the literature,22 over two-thirds of pregnancy-related DTs 
occurred in the anterior abdominal wall and this group 
had a good outcome with a local recurrence below 5%.
The majority of patients underwent surgery as their 
primary treatment with the aim of achieving clear surgical 
margins. The rates of R0 and R1 surgical resections rate in 
our cohort are comparable to published studies despite 
relatively late presentation and large tumour size. 
However, the clinical 
Open Access
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relevance of achieving clear surgical margins and its impact 
on local recurrence is not clearly proven and is the subject of 
conflicting reports in the literature.7 In a series by Gronchi 
et al.23, there was no significant difference in disease-free 
survival in those with microscopically negative or positive 
surgical margins, although there was a trend towards 
significance in patients with microscopically positive margins 
after repeat surgery for local recurrence. In a systematic 
review in 2017 which included 16 studies and 1295 patients,7 
microscopic margins did seem to be an important factor with 
an almost twofold increase in risk of recurrence for patients 
treated with surgery alone and positive microscopic margin. 
In our series, there was no local recurrence detected in those 
with negative surgical margins; however, the sample was too 
small to prove statistical significance. There were three local 
recurrences in patients with microscopically positive margins 
and two local recurrences in patients with macroscopically 
positive margins.
Another subject of contention in the management of DT is the 
role of adjuvant RT following surgery with involved margins, 
with some series showing a local control benefit11,24,25,26 and 
others showing no clear benefit.23,27 In our series, the effect of 
adjuvant RT cannot be determined because of the small 
sample size, heterogeneous treatment regimens and lack of 
adequate follow-up.
Factors associated with recurrence noted in published 
literature include age < 37 years, tumour size > 7 cm in 
diameter and extra-abdominal location.13 The average age of 
patients with recurrence in our series was 25 years compared 
to the overall mean age of 37 years. Neo-adjuvant RT has 
been used with promising results in some centres,28 but in our 
series, only two patients received neoadjuvant RT with one 
proceeding to an R0 resection with no recurrence and the 
other with no response to RT.
Radiotherapy as definitive treatment is an acceptable 
alternative treatment to surgery, with local control rates as 
high as 90.9% at 3 years, including 13.6% complete responses, 
36.4% partial responses and 40.9% stable cases being 
reported.29 Our results showed local control rates well over 
90% in patients treated primarily with RT, with over 77% of 
cases attaining either complete or partial response. The 
average follow-up was close to 5 years, and it is important to 
note that the effects of RT can be slow and ongoing even 
beyond 3 years.29 This response was measured according to 
the RECIST criteria despite its limitations in assessing the 
slow response of some tumours to RT.16
Systemic therapy, previously employed only in situations 
where surgery was not an option (e.g. intra-abdominal FAP-
associated DT), is becoming a more commonly used option in 
the management of DT.12 It consists of non-cytotoxic therapy 
and cytotoxic therapy. The non-cytotoxic therapies include 
hormonal agents (e.g. tamoxifen), anti-inflammatory agents 
(NSAIDS) or biologicals (imatinib, sorafenib).12,30 The 
cytotoxic therapies include chemotherapy agents such as 
doxorubicin, vinblastine and methotrexate.1 Other newer 
local treatments include local ablative therapies using 
thermal or chemical means (e.g. isolated limb perfusion with 
tumour necrosis factor alpha),31 particularly in those poorly 
suited to surgery.10 The use of systemic therapy in our setting 
was limited to only a few patients and in heterogeneous 
treatment settings. Only doxorubicin had a clinically 
significant impact with a good response in one of the patients 
managed with this agent.
Active surveillance for 1–2 years for DT is a management 
strategy that has been adopted by many guidelines in recent 
years.7,10,14,32,33 This strategy has developed because of reports 
that up to 15% of DT regress spontaneously and a significant 
number remain stable with a progression-free survival of up 
to 50% at 5 years.34,35,36 These findings have brought into 
question traditional therapies, primarily surgery, as the 
mainstay of treatment, particularly in cases where surgical 
excision results in significant morbidity.13 The aim of active 
surveillance is to determine which DTs are aggressive and 
will progress and which are indolent, slow-growing or may 
regress. Unfortunately, to date, there are no reliable biological 
markers to distinguish these two groups although genetic 
mutations in the CTNNB1 gene are being investigated.37 
Because of the time frame of our study, none of the patients in 
our study underwent an active surveillance strategy, 
although it is clearly a preferable option to reduce patient 
morbidity and also to limit unnecessary procedures in our 
resource-limited setting. When considering the safe 
implementation of this strategy in our local context, the 
issues of late clinical presentation, delay in referral pathways, 
larger tumour size and poor follow-up will need to be taken 
into consideration.
Limitations
This study has many obvious weaknesses, including being 
retrospective, small sample size, poor follow-up, 
heterogeneous treatment regimens and missing or incomplete 
patient records. This impacts the external validity of the 
study findings. Associations between clinical characteristics 
and outcomes could not be explored further because of the 
small sample size.
Conclusion
This retrospective review of patients affected by DT 
demonstrates the rarity of the condition, the unpredictable 
natural history and the variety of treatment options available. 
While many of our findings mirror previously published 
studies, the mean size of DT in this series was greater, 
possibly because of later presentation or delayed referral. 
The majority of patients in this series underwent surgical 
management and a subset of patients were treated with 
adjuvant or definitive RT. Systemic treatments played a 
minor role. While surgical and RT treatment outcomes in this 
series were acceptable, strong conclusions cannot be drawn 
because of small numbers and inadequate follow-up. Newer 
treatment approaches emphasising active surveillance may 
need to be incorporated into our management protocols but 
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with an awareness of the specific clinical context and through 
an individualised multidisciplinary decision-making process.
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Revisions Required’. 
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editor's decision letter. If needed, you may view the original editor and 
reviewer comments by clicking files linked under the ‘Review Round’. 
- Once your revisions are correctly formatted and prepared, click on 
‘Browse’ to begin uploading your revised manuscript from your desktop. 
Ensure to upload a clean, annotated and point-by-point version as part of 
your revised manuscript submission. 
 
Once all three documents are uploaded, you will need to inform the editor 
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i. Reviewer A comments 
Please find my comments and corrections in line. This is important and 
relevant research that should be published and fits the target audience of 
SAJO. There are however a number of issues that need to be reviewed and 
addressed before it can be deemed fit for publication. The major issues 
concern the unmet secondary aim and its analysis, the reporting format of 
the outcomes and the final conclusion. 
 
Abstract 
• I do not see where the secondary aim is reported on in the results section. Please 
clarify. If this secondary aim was not met in terms of validity and robustness of the 
statistical analysis, I would strongly suggest leaving it out. I have left this out as my 
focus in this study is for it to be a descriptive study and the small numbers and 
incomplete data don’t make it easy to meet the secondary aim 
• Suggest “associated conditions” as in main methods section. Done 
• Please specify if these are mortality and recurrence statistics, rates or ratios? 
Statistics – I have changed the wording to make this clearer 
• See later comments on the use of the terms primary vs definitive. Noted 
• Due to the small numbers and inconsistent follow-up it would be incorrect to 
compare the current outcome results with other series. The conclusion has been 
changed  
• Please explain if this management strategy is being put forward as applicable to all 




• Comment: “condition” is too vague a term to use here when considering the non-
oncological readership of SAJO. Suggest specifying “soft tissue neoplasm.” Done 
• The inability of desmoids to metastasize or dedifferentiate is a distinctive feature 
and I would strongly suggest moving the last sentence of this paragraph to this 
position before making reference to its association with morbidity and mortality. 
Done 
• There is a vast difference in the epidemiology of soft tissue tumour subtypes 
between adults and children. Please explain why it is not relevant to specify the age 
group that this incidence rate refers to or at least the age group most affected by DT. 
Added “adults” to clarify this  
• Review sentence construction. “Other associated conditions…” suggests more than 
one condition being listed in one sentence i.e. pregnancy and antecedent trauma. 
Noted and changed 
• The abbreviation DT was defined in the plural form in the first line. Review for 
consistency of abbreviation use. Good point – changed to be consistent throughout 
article 
• Review reference. The reference to a general medical database is not ideal and also 
outdated (accessed 2 years ago). I would suggest referring to specific studies ie. ref 
7&18, clinical guidelines or update the reference. There was an issue with my 
references following editing and somehow even though I had used a reference 
manager, some of the superscripts lost their link to a reference and became merely 
numbers?! I have gone back and reconnected the numbers to the appropriate 
references  
• Please provide a reference for this statement. This statement could be interpreted to 
imply that RT offers a LR benefit for all DT and this would be incorrect. Ref 7 states 
that “adjuvant RT has not demonstrated a conclusive benefit after first surgery 
regardless of resection margins. However, adjuvant radiotherapy may reduce the 
risk of recurrence after incomplete surgical resection, particularly in patients with 
recurrent tumours. 7 Have changed the statement 
• Suggest clarifying this statement by adding “without any intervention.” Done  
• Consider referring to low- and middle-income countries as this is an accepted 
classification system used by the WHO when comparing world-wide disease 
patterns. Done  
 
Methods  
• Please specify if patients with recurrent DT at first presentation to your centre were 
excluded. I have specified 
• Consider specifying in the introduction that this report concerns adult STS. Done 
• All the diagnoses were based on histology as this was an inclusion criterium for the 
study. Suggest changing this to “biopsy technique used”. Done 
• Consider changing to “immunohistochemistry”. Done 
• Please explain why recurrence rates/ ratios are not mentioned here as it is part of 
the primary aim of the study under “Aim” and reported in detail in “Results”. I have 
corrected this omission  
• Please specify from which time-point follow-up was calculated. Done 
 
Statistical Considerations 
• Bivariate data reporting in terms of reporting the margin status of the patients who 
recurred or did not recur as in the “Recurrence” section is valid. This does however 
not constitute bivariate analysis as the low numbers do not allow for this. I have 
changed this and removed Bivariate analysis, which was attempted but not included. 
 
Results 
• Avoid duplication of detailed results, i.e. statistics and full breakdown, in both the 
text of the results section and in tables. I strongly suggest only highlighting selected 
results in the text. I will attempt to take out some 
• Suggest adding subheadings i.e. Patient and tumour characteristics, Treatment, 
Follow-up and Outcomes. Good Idea – I have done so  
• Suggest replacing with: The majority of patients (86%) were female. Done  
• In a tumour that typically targets a defines age group i.e. the fourth decade, it would 
be more relevant to report the median age of the cohort. This would also be more 
comparable to the same statistic in other series as is done in the discussion. Have 
changed to “median” 
• Consider grouping limb lesions together as is the trend in most reported series on 
DT. Done  
• Important to specify whether the pain was related to the mass and not arising from 
somewhere else. Suggest: “painful mass”. Done  
• Important to indicate in some way that the pain was related to the DT. Suggest: 
“localised pain”. Done  
• Please specify if this refers to the time of formal diagnosis or when the patient 
became aware of the lesion? Have specified 
• It would be relevant to indicate if any patient had more than one associated factor 
i.e. pregnancy and surgery, as it has been reported that pregnancy related surgery 
can be associated with DT. Found one patient that did 
• Indicate percentage of cohort tested for -catenin (54.3%) as well as percentage 
staining positive out of the whole cohort (51.4%). It would be a misrepresentation to 
report the rate of stain positivity as 95% (In discussion) if just more than half of the 
cohort were tested. I have modified this to give a more honest representation 
• Suggest summarizing as “Only 17% of cases were not primarily managed by the ……” 
I did try this but it ended up me saying the same thing but in reverse and seemed a 
bit more clumsy – so have left it. I’m happy to change it but not quite sure how. 
• In view of the recommendation made in the conclusion, it would be relevant to 
specify in how many cases this review occurred before the first definitive treatment 
intervention i.e. surgery or RT. Unfortunately I do not know the answer  
• Using the terms “primary” and “definitive” interchangeably in the following 3 
sections could lead to confusion. Does primary refer to the first/ up-front 
intervention or the definitive/ most important intervention? Suggest using either 
one of these terms consistently or clarifying the difference between the 2 in the text. 
Have used only one term to make it clearer and more consistent.  
• According to this pie chart 59 patients had surgery or RT or both. That would mean 
that the 2 neo-adjuvant RT patients mentioned under “Surgery and Radiotherapy” 
are included in the 46 under primary surgery and that the 13 Primary radiotherapy 
cases represent the 13 cases discussed under “Radiotherapy as definitive 
treatment”. It would then be relevant to mention that 2 of the 46 patients had neo-
adjuvant RT as reported in “Surgery and Radiotherapy”. One would then deduce that 
these 2 patients represent one of the 2 R2 cases mentioned here and the other 
forms part of the R0 cohort mentioned here. Please confirm if this is correct. It also 
makes the special mentioning of the patient who had “palliative surgery” for tumour 
necrosis confusing. Was this patient also included in the 11 patients who had surgery 
and radiotherapy? The deductions in this comment are correct. The patient who 
underwent a palliative resection does fall into the category of surgery. Detail of the 
two palliative surgery cases was removed in order to improve clarity.  
 
Surgery  
• Please explain the specific reference and setting apart of these 2 patients. One could 
argue that the debulking procedure for bowel obstruction was in fact a planned R2 
resection and that the second case with tumour necrosis should be grouped under 
the definitive RT cohort with special mention that the patient ended up requiring 
salvage surgery. At the same time it could also refer to a case of neo-adjuvant RT 
followed by planned surgery. See other comments related to this second patient as 
well. I have removed some of the detail of some of these patients and tried to make 
it clearer 
• Technically the RT and not the surgery was the primary treatment in this case unless 
it was neo-adjuvant RT followed by planned surgery. See other comments on this 
patient. This is one of the “neo-adjuvant” cases  
• This abbreviation is unnecessary as this term is not used again in the article. Well 
picked up 
• Consider changing to “required”. Done  
• Suggest referring to this table in the text to place it into context. Done  
• Suggest reformatting this column as a list with complication first and number of 
cases second. Suggest reformatting by adding column right with “management”. 
Suggest deleting. CD Grade 5 implies death already. Complication table adjusted  
 
Surgery and RT  
 
• Please specify if this includes the patient who had surgery for tumour necrosis 
mentioned under “Surgery”. Specified 
• Neo-adjuvant RT is not a well described treatment modality in DT as it is for other 
adult STS. Please explain the rationale and supporting data for this management 
strategy further and if it was in fact planned neo-adjuvant RT or definitive RT with 
salvage surgery due to progression. This was planned neoadjuvant radiotherapy 
which was an individualised MDT decision based on the difficult surgical options for 
the patient’s concerned. 
• It would be relevant to specify if these margins were R1 or R2 as R2 is a known risk 
factor for increase local recurrence. Have specified  
• This sentence and the last part of the final sentence is somewhat out of place here 
as recurrence is discussed under a later heading. See comment on “Recurrence” 
heading. Have adjusted this  
• Please specify if this was “adequate follow-up” as defined later. Yes – all for more 
than a year 
 
RT  
• Please specify if this cohort includes the patient who had surgery for tumour 
necrosis mentioned under “Surgery”. No – this patient is in the “surgery” group  
• The reference to non-definitive RT in this sentence can be confusing. Suggest moving 
this sentence to the end of the paragraph. Have done so 
• It would be more relevant to report the median and dose range used as RT dose 
prescriptions are pre-defined according to protocol and can therefore be seen as 
categorical rather then continuous. Done  
• Please specify if this was the dose ultimately delivered or the planned/ prescribed 
dose. Delivered  
• Using the terms “primary” and “definitive” interchangeably could lead to confusion. 
Suggest using definitive consistently. Will use “definitive” 
• These 3 sentences are somewhat out of place here as Systemic treatment, follow-up 
and recurrence are discussed under later headings. See comment on “Recurrence” 
heading. This is a good point I have changed it to “treatment and outcomes” as 
putting all the outcomes together doesn’t seem to work as it is quite different 
comparing outcome post surgery and post RT 
 
Recurrence 
• There are multiple issues with the reporting of outcomes in this article: 1. This section 
only reports the recurrence after primary surgery. This would make the heading 
somewhat misleading. The recurrence after definitive RT is reported in the 
“Radiotherapy as definitive treatment” section. Please group all reporting of 
outcomes under one heading to avoid confusion. I have included outcomes with 
treatment – to make it easier to understand 2. Suggest moving this section to after 
the “Follow-up” section as the quality of outcome data depends on the quality of 
follow-up which in this cohort was one of its weaknesses. Done 3. The decision to 
report outcomes by dividing the cohort into those patients with more or less than one-
year follow-up is somewhat confusing and dilutes the significance of the results. Ref 7 
reports that most recurrences occur within 2 years of surgery. Please explain why this 
strategy was chosen. Why one year was used as follow up? This was a time length 
decision as most patient who had follow up attended clinic appointments for the first 
year. We acknowledge that this is an inadequate timeframe hence strong conclusions 
cannot be drawn about local recurrence and outcomes. 4. The reporting of deaths is 
grouped under “follow-up” whereas it would fit better with the other outcomes under 
one heading. Will do so 
• Specify whether this was based on clinical examination alone or on radiological 
findings. Done 
• Specify “at last follow-up.” Done  
• These are the results that could be used for bivariate analysis (see comment on 
Secondary aim and statistical analysis) to test for correlation or association. 
Unfortunately, the low numbers do not allow for this. It could be visually represented 
in a stacked bar or column chart. As previously mentioned – decided to remove 
“secondary outcome” 
• Please explain the relevance of reporting of the age at time of recurrence. Ref 18 
indicates that age at diagnosis ≤37yrs is associated with worse PFS outcomes, this 
would be a more relevant finding to report. It would also be relevant to report RFS (in 
months post-op) if possible. This is a mistake – it was age at diagnosis, and this has 
been corrected 
• Suggest referring to this figure in the text to place it into context. Suggest adding foot-
note specifying adequate follow-up as ≥1 year follow-up. Suggest placing “No 
recurrence” arm on the left and “Recurrence” arm on the right of the flow diagram. 
All done  
• It would be relevant to have a similar flow chart for definitive RT patients or to 
expand the current chart to include them. I have done so 
 
Systemic Treatment 
• Please specify where the 3 patients referred to under “Radiotherapy as definitive 
treatment” (Systemic therapy was given to the 3 patients who had no response to 
RT) fit into this section. Please explain how these 4 patients relate to the 2 patients 
who received primary systemic therapy in the pie chart in Figure 1. Please specify 
timing of this treatment i.e. pre-surgery or after local recurrence? I have changed 
this section in an attempt to clarify “systemic therapy” comments 
• The decision to divide the cohort into those patients with more or less than one-year 
follow-up is somewhat confusing and dilutes the significance of the results. I suggest 
reporting median follow-up length from first treatment intervention for all patients 
with any known follow-up visit. Please explain why Kaplan Meyer curves cannot be 
used to estimate a local recurrence rate at certain relevant time intervals i.e. 5yrs, 
12m or 6m (with censoring of the patients at last follow-up). Given the incomplete 
data and small sample size, time to event data were not analysed further.  
 
Follow-up 
• Please specify if follow-up was according to a strict schedule and if it entailed clinical 
examination only or radiological investigations. It was extremely variable – no strict 
schedule 
• It would be more relevant to report the median follow-up duration if one case is an 
outlier. Done 
• These two sentences report outcomes and should be grouped with the reports on 
recurrence under one heading preferably following this one. Have made a 
“mortality” subheading  
• Suggest specifying if this was due to progressive DT or complications of its 
treatment. Done  
 
Discussion  
• This is an incorrect deduction as 46% of the cases were not tested for -catenin at 
all. At most one can claim that at least 51% of the patients were BC positive. Noted 
and tried to explain this more accurately  
• Please explain why it would not be relevant to mention the relatively high rates of R0 
and R1 resections achieved in this cohort for upfront surgery despite large 
presenting tumours and likely surgical service constraints. The results look good 
(from my calculations) and quite comparable to those in Ref 7. Have done so 
• Suggest adding “for local recurrence”. Done  
• Please confirm if this sentence refers to the bivariate analysis mentioned in the 
secondary aims. If this is what it refers to, I would suggest stating that the small 
sample size, heterogenous treatment regimens and lack of follow-up precluded 
analyses of any associations between descriptive factors and outcomes. Have edited  
• Please explain the relevance of this sentence. It might be more relevant to report on 
the number of recurrences in the patients with positive margins and adequate 
follow-up who had surgery only here. Removed sentence  
• Suggest changing to “cannot be determined due to the small sample size, 
heterogenous treatment regimens and lack of follow-up. Done  
• Please explain the relevance of this statement. Would it not be more relevant to 
discuss the number of recurrences in patients with positive surgical margins and 
adequate follow-up that did and did not have RT?   Removed  
• Please clarify if this age (25yrs) refers to the age at diagnosis or at time of recurrence 
as mentioned earlier “The average age at time of recurrence was 25 years (range: 18 
– 32)”. Please note that the prognostic data in Ref 18 refers to age at diagnosis and 
that 13% of the patients in that cohort were <18yrs of age. Age of diagnosis – 
corrected  
• Please provide specific reference within ref 28 for this statement. This is true for STS 
in general, but not for DT. Correct reference added 
• It is also relevant to note that these cases were all deemed irresectable and 
therefore were probably in a poorer prognostic group than the patients who had 
upfront surgery. Please comment on this. Section edited – have not specifically 
commented on this 
• Please explain the reference to resectable DT here. It is my understanding that AS is 
promoted for asymptomatic or minimally symptomatic DT whether resectable or not 
as an initial treatment option to monitor for possible spontaneous regression or 
stability. Definitive intervention would then be triggered by progression or 
progressive symptoms. Have taken out “resectable” 
• It is interesting to consider the referral pathways of your setting and whether 
tumours that are referred to a tertiary referral centre might not already have been 
observed clinically for a long period of time in the primary or secondary care setting 
and only get referred when they don’t regress spontaneously or become 
symptomatic. This represents a form of referral bias. It is interesting  
• Consider summarizing the inherent study weaknesses under one heading or 
paragraph. Have done so  
 
Conclusion  
• Please provide a reference for this caveat. Caveat was removed  
 
ii. Reviewer C comments 
 
Thank for the opportunity to review the manuscript. It is definitely of 
importance and relevance across various medical specialties. For 
comprehensive inputs and suggestions please see attached manuscript with 
Track Changes. 
 






b) Methods: Ok 
 
c) Results: Check denominators and be consistent with style of reporting.  
 
d) Results: Need to be re-done to be based on findings from the study. Has been changed  
 




a) Otherwise Ok. 
 
b) Ensure that references follow each other sequentially. Check appearance 
of References 11-15. Problem with references sorted out – technical issue 
 
c) Consider including information on morbidity associated with resection of 
DT and therefore citation of an article covering the Clavien-Dindo 
Classification within the introduction. Have done so 
 




a) Reasonably ok. 
 
b) Add post-operative complications amongst data to be collected. Done  
 




a) Be consistent regarding reporting: Numerator/Denominator (%). Done  
 
b) Use tables and figures strategically and not repeat everything which is 
contained in them in the text. Okay  
 
c) Caption for tables on top and for figures below. Done  
 
d) Captions should be comprehensive i.e. should be able to tell the story. Have edited as 
suggested  
 
e) Tables and figures should appear immediately after they have been 
cited/referred to. Good point 
 
f) Revise grammar. 
 
g) Appropriate use of numbers and words (<10: words in general). Verify 
statement regarding recurrence in patients whose follow-up was inadequate. 
Number operated with curative intent 44/46, should be clear. Have edited this section  
 




a) Report predominately as "3rd person". 
 
b) Where more than one study is implied in a statement, more than one 
reference should be cited e.g. several studies but only reference 17 is 
cited. Reference issue addressed  
 
c) Please ensure that references are appearing sequentially. Done  
 
d) Focused the discussion on findings from the study in relation with key 
issues covered/highlighted in the introduction (underlined) to avoid making 
it appear like a review article. Have made changes  
 
e) Check grammar. 
 





a) Needs to be re-done. Have done so  
 
b) It is too generic and not hinging on findings from the study. There are a 
number of significant conclusions which can be made 




a) Happy in overall. 
 
b) Check the sequence Mistake corrected  
 
 
